Shanghai RAAS major shareholder completes stock increase plan

Shanghai RAAS Blood Products (SZSE:002252) announced that its controlling shareholder, Hai Ying Kang (Qingdao) Medical Technology, has completed its planned increase in the company's shareholding. From January 7, 2025, to February 26, 2025, Hai Ying Kang acquired 72,439,700 shares through the Shenzhen Stock Exchange's centralized bidding system, representing 1.09% of the company's total share capital. The total investment amounted to approximately RMB 496.83 million (excluding transaction costs). With this increase, Hai Ying Kang and its parties acting in concert, now hold 27.70% of the company's shares, demonstrating the controlling shareholder’s confidence in the company’s long-term value and commitment to enhancing investor confidence. Hai Ying Kang has committed to not reduce its holdings within the statutory period following the completion of this share increase.